Mayne Pharma Group
Mayne Pharma Group Limited is a specialty pharmaceutical company listed on the ASX, focused on commercializing pharmaceuticals and improving patient access to life-enhancing medications. The company has a 40-year track record of innovation in developing oral drug delivery systems, offering a portfolio of branded and generic drugs in therapeutic areas like women's health and dermatology.
Short position
Mayne Pharma Group (ASX:MYX) has 2.23% of its shares on issue reported as short positions as of 5 Oct 2026, or about 1,825,643 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has fallen 0.32 percentage points. Its highest recorded short interest was 13.53% in May 2017. MYX is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Mayne Pharma Group (MYX) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26), figures in AUD, the reporting currency
- Revenue
- $378.4Mvs n/a
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- $24.5Mvs n/a
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- $0.23vs n/a
- Yahoo Finance, as at 29 Sep 2026
- Rev YoY
- n/aFY
- EPS YoY
- n/aFY
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 64.2%
- Operating margin
- 20.7%
- Net margin
- 6.5%
- FCF margin
- 2.8%
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- 0.43×
- Net cash (excl. leases)
- $41.0M
- Net debt / EBITDA
- −0.3×
- Current ratio
- 1.3×
- Interest cover
- 2.0×
- Cash dividends paid / net profit
- n/a
- Market cap
- $216.1M
- P/E
- 11.6×
- P/B
- 0.6×
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY24 | FY23 | FY22 |
|---|---|---|---|---|
| Revenue | $378.4M | $387.9M | $182.4M | $423.9M |
| Gross profit | $242.8M | $218.3M | $82.3M | $170.1M |
| Operating income | $78.2M | −$139.3M | −$190.7M | −$83.1M |
| EBITDA | $138.6M | −$87.1M | −$175.9M | −$104.6M |
| EBIT | $74.9M | −$155.6M | −$241.3M | −$185.7M |
| Interest expense | $39.2M | $34.5M | $28.4M | $32.1M |
| Pretax income | $35.8M | −$190.1M | −$269.7M | −$217.8M |
| Tax | $4.6M | −$21.5M | $47.7M | $56.1M |
| NPAT | $24.5M | −$174.2M | $117.2M | −$263.3M |
| Net interest income | −$35.8M | −$27.9M | −$22.1M | −$32.0M |
| EPS basic | $0.31 | −$2.12 | $1.42 | −$3.20 |
| EPS diluted | $0.23 | −$2.12 | $1.42 | −$3.20 |
| Shares | 81.2M | 81.2M | 83.4M | 88.2M |
Financial reports
The company's own filings, newest first
- 2026 Full Year Results Media ReleaseFull Year Results27 Aug 2026via asx_announcements
- 2026 Appendix 4E and Annual ReportAnnual Results27 Aug 2026via asx_announcements
- 2026 Full Year Results Investor PresentationFull Year Results27 Aug 2026via asx_announcements
- Half Yearly Report and AccountsHalf Year Results23 Feb 2026via asx_announcements
- 2026 Half Year Investor PresentationHalf Year Results23 Feb 2026via asx_announcements
- 2026 Half Year Media ReleaseHalf Year Results23 Feb 2026via asx_announcements
- Mayne Pharma 2025 Half Year Results Media Release26 Feb 2025Mayne Pharma’s CEO, Mr Shawn Patrick O’Brien said “We are very pleased with the performance of the Mayne Pharma business in the first half, with robust revenue growth recorded, particularly within our Women’s Health segment.” “Our broad portfolio in Dermatology and Women’s Health leverages our existing commercial infrastructure and strengthens our market presence. Our refined US channel strategy has not only increased margins but importantly, is providing greater patient access.”Learn moreHalf Year Results31 Dec 2025via crawler
- Mayne Pharma Enters Into A Scheme Implementation Deed With Cosette Pharmaceuticals, Inc21 Feb 2025Mayne Pharma Group Limited announces that it has entered into a scheme implementation deed with Cosette Pharmaceuticals, Inc. under which Cosette has agreed to acquire 100% of the shares in Mayne Pharma by way of a Scheme of Arrangement at a price of A$7.40 per share.Learn moreFinancial Report31 Dec 2025via crawler
- FY25 Results Presentation (PDF)Investor Presentation31 Dec 2025via crawler
- HY25 Results Presentation (PDF)Investor Presentation31 Dec 2025via crawler
Showing 10 of 26 reports